{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:32:46Z","timestamp":1785342766415,"version":"3.55.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100024334","name":"State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003803","name":"University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"University Grants Committee Research Grants Council","doi-asserted-by":"publisher","award":["10,617,014"],"award-info":[{"award-number":["10,617,014"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.euroneuro.2025.05.003","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T06:35:43Z","timestamp":1747982143000},"page":"58-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Comparative mortality risk of antipsychotics in 41,695 patients with schizophrenia: an 11-year population-based cohort study in Hong Kong"],"prefix":"10.1016","volume":"96","author":[{"given":"Catherine Zhiqian","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe Kwun-Nam","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine Sau-Man","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9360-6244","authenticated-orcid":false,"given":"Simon Sai-Yu","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChristophU","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3581-8895","authenticated-orcid":false,"given":"Wing-Chung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2025.05.003_bib0001","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41380-024-02694-3","article-title":"All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis","volume":"30","author":"Aymerich","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0002","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. B Methodol."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0003","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.japh.2022.08.006","article-title":"Systematic review of community pharmacist administration of long-acting injectable antipsychotic medications","volume":"63","author":"Black","year":"2023","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2020.08.026","article-title":"Mortality risk from long-term treatment with antipsychotic polypharmacy vs monotherapy among adults with serious mental illness: a systematic review and meta-analysis of observational studies","volume":"223","author":"Buhagiar","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0005","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/ph14030238","article-title":"Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences","volume":"14","author":"Carli","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102294","article-title":"Life expectancy and years of potential life lost in people with mental disorders: a systematic review and meta-analysis","volume":"65","author":"Chan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0007","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41380-024-02723-1","volume":"30","author":"Chan","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0008","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1192\/j.eurpsy.2024.1758","article-title":"Risk of congenital malformations associated with first-trimester exposure to antipsychotics: a propensity score-weighted population-based cohort study","volume":"67","author":"Chan","year":"2024","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0009","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1192\/bjp.2020.248","article-title":"Risk of mortality and complications in patients with schizophrenia and diabetes mellitus: population-based cohort study","volume":"219","author":"Chan","year":"2021","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0010","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/schbul\/sbaa013","article-title":"Mortality, revascularization, and cardioprotective pharmacotherapy after acute coronary syndrome in patients with psychotic disorders: a population-based cohort study","volume":"46","author":"Chang","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0011","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic. Dis."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0012","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.schres.2015.10.005","article-title":"Survival analysis of the use of first and second generation antipsychotics among patients suffering schizophrenia: a nationwide population-based cohort study","volume":"169","author":"Chen","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0013","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.schres.2023.07.014","article-title":"Clozapine and its protective effect on all-cause, natural, and suicide mortality in patients with schizophrenia: a nationwide cohort study in Taiwan","volume":"268","author":"Chen","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0014","first-page":"307","article-title":"Principles-based medical informatics for success\u2013how Hong Kong built one of the world\u2019s largest integrated longitudinal electronic patient records","volume":"129","author":"Cheung","year":"2007","journal-title":"Stud. Health Technol. Inform."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105454","article-title":"An umbrella review of adverse effects associated with antipsychotic medications: the need for complementary study designs","volume":"155","author":"Chow","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0016","first-page":"443","article-title":"Antipsychotic combinations versus monotherapy in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0017","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40263-022-00932-2","article-title":"A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia","volume":"36","author":"Correll","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0018","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","article-title":"Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophrenia"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0019","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0021","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1176\/appi.ajp.2012.12050599","article-title":"Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study","volume":"170","author":"Crump","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0022","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108236","article-title":"Clozapine\u2019s multiple cellular mechanisms: what do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia","volume":"236","author":"de Bartolomeis","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0024","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/j.2051-5545.2011.tb00036.x","article-title":"Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0026","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/bjb.2018.67","article-title":"Barriers to using clozapine in treatment-resistant schizophrenia: systematic review","volume":"43","author":"Farooq","year":"2019","journal-title":"BJPsych Bull."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0027","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1192\/bjp.2024.88","article-title":"Mortality associated with clozapine: what is the evidence?","volume":"225","author":"Fernandez-Egea","year":"2024","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0028","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"Galling","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0029","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19ac13118","article-title":"Antipsychotic polypharmacy in schizophrenia: why not?","volume":"81","author":"Guinart","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0030","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14656566.2023.2181073","article-title":"Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges","volume":"24","author":"Haddad","year":"2023","journal-title":"Expert Opin. PharmacOther"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0031","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0032","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2215-0366(24)00314-6","article-title":"Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis","volume":"11","author":"H\u00f8jlund","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0033","series-title":"Hospital Authority Statistical Report: 2018\u20132019","year":"2019"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.8810","article-title":"Comparison of long-acting injectable antipsychotics with oral antipsychotics and suicide and all-cause mortality in patients with newly diagnosed schizophrenia","volume":"4","author":"Huang","year":"2021","journal-title":"JAMa Netw. Open"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0035","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0036","first-page":"664","article-title":"Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis","volume":"44","author":"Jia","year":"2022","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0037","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/0706743718772522","article-title":"Delayed initiation of clozapine continues to be a substantial clinical concern","volume":"63","author":"John","year":"2018","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0038","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12546","article-title":"Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics)","volume":"80","author":"Kane","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0039","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/bs.apha.2017.09.009","article-title":"Unique effects of clozapine: a pharmacological perspective","volume":"82","author":"Khokhar","year":"2018","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0040","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00406-022-01453-1","article-title":"Antipsychotic utilization patterns in pregnant women with psychotic disorders: a 16-year population-based cohort study","volume":"273","author":"Law","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0041","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0042","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1176\/appi.ajp.20240738","article-title":"Antipsychotic drugs: a concise review of history, classification, indications, mechanism, efficacy, side effects, dosing, and clinical application","volume":"181","author":"Leucht","year":"2024","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0043","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0640","article-title":"Development and validation of a machine learning-based model of mortality risk in first-episode psychosis","volume":"7","author":"Lieslehto","year":"2024","journal-title":"JAMa Netw. Open"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0044","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/schbul\/sbac014","article-title":"Primary nonadherence to antipsychotic treatment among persons with schizophrenia","volume":"48","author":"Lieslehto","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.euroneuro.2022.12.011","article-title":"Prevention of suicide by clozapine in mental disorders: systematic review","volume":"69","author":"Masdrakis","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0046","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","article-title":"Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies","volume":"76","author":"Masuda","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0047","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia-an overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0048","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.schres.2021.01.006","article-title":"Decreased cardiovascular death in schizophrenia patients treated with antipsychotics: a Korean national cohort study","volume":"228","author":"Oh","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0049","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231158152","article-title":"Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia","volume":"13","author":"Qubad","year":"2023","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0050","series-title":"R: A Language and Environment for Statistical Computing","year":"2024"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0051","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1192\/bjp.bp.114.157685","article-title":"Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China","volume":"207","author":"Ran","year":"2015","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0052","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1176\/ps.2007.58.4.482","article-title":"Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia","volume":"58","author":"Shi","year":"2007","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0053","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0054","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.euroneuro.2023.12.010","article-title":"Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: a systematic review and meta-analysis","volume":"80","author":"Solmi","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.euroneuro.2024.07.009","article-title":"Effects of antipsychotic treatment on cardio-cerebrovascular related mortality in schizophrenia: a subanalysis of a systematic review and meta-analysis with meta-regression of moderators","volume":"88","author":"Solmi","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0056","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther. Clin. Risk. Manage"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0057","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/eip.12278","article-title":"Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia","volume":"10","author":"Stevens","year":"2016","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0058","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0140-6736(16)32380-7","article-title":"Socioeconomic status and the 25 \u00d7 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1\u00b77 million men and women","volume":"389","author":"Stringhini","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0059","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/schbul\/sbaa111","article-title":"Comparative effectiveness of antipsychotics for risk of attempted or completed suicide among persons with schizophrenia","volume":"47","author":"Taipale","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0060","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","article-title":"Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia","volume":"197","author":"Taipale","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0061","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2215-0366(24)00366-3","article-title":"Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: a population-based cohort study","volume":"12","author":"Taipale","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0062","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0063","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2021.08.015","article-title":"A nationwide study of the risk of all-cause, sudden death, and cardiovascular mortality among antipsychotic-treated patients with schizophrenia in Taiwan","volume":"237","author":"Tang","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0064","article-title":"Risks of all-cause death and completed suicide in patients with schizophrenia\/schizoaffective disorder treated with long-acting injectable or oral antipsychotics: a population-based retrospective cohort study in Taiwan","volume":"65","author":"Tang","year":"2021","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0065","article-title":"Using time dependent covariates and time dependent coefficients in the cox model","author":"Therneau","year":"2017","journal-title":"Surviv. Vignettes"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0066","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/eip.12683","article-title":"Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: a literature review","volume":"13","author":"Thien","year":"2019","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0067","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","article-title":"A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia","volume":"168","author":"Tiihonen","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0068","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0069","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0070","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/appi.ajp.2015.15050618","article-title":"Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study","volume":"173","author":"Tiihonen","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0071","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","article-title":"Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia","volume":"76","author":"Tiihonen","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0072","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/schbul\/sbu164","article-title":"Antipsychotic treatment and mortality in schizophrenia","volume":"41","author":"Torniainen","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0073","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1192\/j.eurpsy.2024.1816","article-title":"The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force","volume":"68","author":"Verdoux","year":"2025","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0074","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/schbul\/sby052","article-title":"Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years","volume":"45","author":"Vermeulen","year":"2019","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0075","doi-asserted-by":"crossref","DOI":"10.1177\/20451253241257062","article-title":"Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis","volume":"14","author":"Vita","year":"2024","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0076","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/appi.ajp.2017.16091097","article-title":"Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia","volume":"174","author":"Wimberley","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0077","first-page":"14","article-title":"Global neuropsychopharmacological prescription trends in adults with schizophrenia, clinical correlates and implications for practice: a scoping review","author":"Ying","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0078","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1177\/00048674221121575","article-title":"Mortality rates in people with first diagnosis of schizophrenia-spectrum disorders: a 5-year population-based cohort study","volume":"57","author":"Yung","year":"2023","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0079","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.euroneuro.2019.12.107","article-title":"Mortality in patients with schizophrenia admitted for incident ischemic stroke: a population-based cohort study","volume":"31","author":"Yung","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0080","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.euroneuro.2019.12.107","article-title":"Mortality in patients with schizophrenia admitted for incident ischemic stroke: a population-based cohort study","volume":"31","author":"Yung","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.05.003_bib0081","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2018.02.12","article-title":"Time-varying covariates and coefficients in Cox regression models","volume":"6","author":"Zhang","year":"2018","journal-title":"Ann. Transl. Med."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X25000860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X25000860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:29:00Z","timestamp":1749706140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X25000860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":81,"alternative-id":["S0924977X25000860"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.05.003","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative mortality risk of antipsychotics in 41,695 patients with schizophrenia: an 11-year population-based cohort study in Hong Kong","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. and ECNP. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}